ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 8ÔÂ29ÈÕ£¬£¬£¬£¬£¬¶àÂêÒ½Ò©EGFR/c-METË«¿¹ADC²úÆ·DM005£¬£¬£¬£¬£¬Õýʽ»ñµÃÃÀ¹úFDA INDÅú×¼£¬£¬£¬£¬£¬Ë³Ó¦Ö¢ÎªÊµÌåÁö¡£¡£¡£¡£
2. 8ÔÂ29ÈÕ£¬£¬£¬£¬£¬ºãÈðÒ½Ò©Ðû²¼Í¨¸æ£¬£¬£¬£¬£¬¹«Ë¾¼°×Ó¹«Ë¾³É¶¼Ê¢µÏÒ½Ò©ÓÐÏÞ¹«Ë¾ÊÕµ½¹ú¼ÒÒ©¼à¾ÖÅú׼ǩ·¢¹ØÓÚHRS-1167Ƭ¡¢HRS-5041ƬºÍSHR2554ƬµÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬£¬£¬£¬£¬½«ÓÚ½üÆÚ¿ªÕ¹ÁÙ´²ÊÔÑé¡£¡£¡£¡£ÏêϸΪ£ºHRS-5041ƬÁªºÏHRS-1167Ƭ¡¢SHR2554Ƭ¡¢´×Ëá°¢±ÈÌØÁúƬ£¨II£©¡¢¶àÎ÷ËûÈüÓÃÓÚÍíÆÚǰÏßÏÙ°©µÄÁÙ´²ÊÔÑé¡£¡£¡£¡£
3. 8ÔÂ29ÈÕ£¬£¬£¬£¬£¬CDE ¹ÙÍøÏÔʾ£¬£¬£¬£¬£¬°¢Ë¹Àû¿µ£¨AstraZeneca Pharmaceuticals LP£©É걨µÄ5.1ÀàÐÂÒ©²¼µØÄεÂÁòËáɳ¶¡°·´¼ÎüÈëÆøÎí¼Á»ñÁÙ´²ÊÔÑéĬʾÔÊÐí£¬£¬£¬£¬£¬Æä˳Ӧ֢ΪÓÃÓÚ18Ëê¼°ÒÔÉÏÏø´»¼Õß°´ÐèÖÎÁƺÍÔ¤·ÀÖ§Æø¹ÜËõ¶Ì£¬£¬£¬£¬£¬ÒÔ¼°½µµÍ¼±ÐÔ±¬·¢Î£º¦¡£¡£¡£¡£
4. 8ÔÂ29ÈÕ£¬£¬£¬£¬£¬±±¾©¸£ÔªÒ½Ò©¹É·ÝÓÐÏÞ¹«Ë¾Ðû²¼Í¨¸æ³Æ£¬£¬£¬£¬£¬¹«Ë¾²úÆ·ÄáÂó½ÇÁÖÆ¬£¨¹æ¸ñ£º10mg£©¡¢ÃÀ°¢É³Ì¹¼ØÆ¬£¨¹æ¸ñ£º40mg£»£»£»80mg£©»ñÅúÉÏÊС£¡£¡£¡£ÄáÂó½ÇÁÖÆ¬ÊÇÓÉ»ÔÈð¹«Ë¾ÑÐÖÆµÄÒ»ÖÖ°ëºÏ³ÉÂó½ÇÉúÎï¼î£¬£¬£¬£¬£¬ÓÃÓÚ¸ÄÉÆÓÉÓÚÄÔ¹£ÈûºóÒÅÖ¢ÒýÆðµÄÒâÓûµÍÏ£»£»£»Ò²ÊÊÓÃÓÚѪ¹ÜÐÔ³Õ´ô£¬£¬£¬£¬£¬ÓÈÆäÔÚÔçÆÚÖÎÁÆÊ±¶ÔÈÏÖª¡¢Ó°ÏóµÈÓиÄÉÆ£¬£¬£¬£¬£¬²¢ÄܼõÇá¼²²¡ÑÏÖØË®Æ½¡£¡£¡£¡£ÃÀ°¢É³Ì¹¼ØÆ¬ÊÇÓÉÎäÌïÖÆÒ©ÑÐÖÆµÄÒ»¿îѪ¹ÜÖ÷ÒªËØIIÊÜÌå×èÖͼÁ£¬£¬£¬£¬£¬ÊÊÓÃÓÚÖÎÁƳÉÈËÔ·¢ÐÔ¸ßѪѹ¡£¡£¡£¡£
1. 8ÔÂ28ÈÕ£¬£¬£¬£¬£¬°Ý¶úÐû²¼ÓëNextRNA Therapeutics¸æ¿¢ÏàÖú£¬£¬£¬£¬£¬Ë«·½½«ÅäºÏ¿ª·¢Á½Ïî°ÐÏò³¤Á´·Ç±àÂëRNA£¨lncRNA£©µÄDZÔÚfirst-in-classС·Ö×ÓÁÆ·¨£¬£¬£¬£¬£¬½øÒ»²½ÔöÇ¿°Ý¶úµÄ¾«×¼Ö×ÁöѧÑз¢¹ÜÏß¡£¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬£¬¸´µ©´óѧÁ¥ÊôÖÐɽҽԺÖ×ÁöÄÚ¿ÆÁõÌìÊæ½ÌÊÚÍŶÓÔÚ¡¶Nature Communications¡·£¨IF=14.7£©ÔÓÖ¾ÉϽÒÏþÁËÌâΪ¡°Tislelizumab Plus Cetuximab and Irinotecan in Refractory Microsatellite Stable and RAS Wild-Type Metastatic Colorectal Cancer: a single-arm phase 2 study¡±µÄÁÙ´²Ñо¿Ð§¹û£¬£¬£¬£¬£¬ÎªMSSÐÍÍíÆÚ³¦°©»¼ÕßÌṩÁËÒ»ÖÖеÄÖÎÁƼƻ®¡£¡£¡£¡£
[1]Tianshu Liu, et al. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. Nature Communications.2024;15:7255.
Ïà¹ØÐÂÎÅ